Coronavirus | Wait for vaccine likely to end soon, says Harsh Vardhan

SII CEO Adar Poonawalla says his company has 40-50 million doses of COVISHIELD stockpiled

December 28, 2020 07:30 pm | Updated December 29, 2020 05:27 pm IST - NEW DELHI

Union Health Minister Harsh Vardhan. File

Union Health Minister Harsh Vardhan. File

India should be able to make available a COVID-19 vaccine in a matter of weeks now to its population, Union Health Minister Dr. Harsh Vardhan said on Monday while launching Serum Institute of India’s (SII) Pneumococcal Cojugate Vaccine: Pneumonsil.

“Everybody is desperately waiting for a vaccine, but the wait is likely to end soon,’’ he stated.

Also read: Coronavirus | Our biggest weapons now are mask and sanitizer, says Harsh Vardhan

SII is testing and manufacturing the Oxford-AstraZeneca COVID-19 vaccine candidate, which has emerged as the front runner in the race for getting an emergency use approval in the country. It is awaiting approval in the U.K.

SII CEO Adar Poonawalla said that while a positive news should be expected soon, “we cannot compromise on the safety of the vaccine and so must allow the regulatory authorities to do their work without any pressure.”

Also read: Coronavirus | Harsh Vardhan for more vigilance in entire festive season

The company had 40-50 million doses of vaccine COVISHIELD stockpiled. “Once we get regulatory approvals in a few days, it’ll be down to the government to decide how much they can take and how fast. We will be producing around 300 million doses by July 2021.” he stated.

Vaccine shortage

Mr. Adar, however, noted that the first six months of 2021 would see a vaccine shortage globally.

Also read: Coronavirus | Healthcare workers, people aged above 65 will be given priority for COVID-19 vaccine: Harsh Vardhan

“Nobody can help that. But we will see easing off by August-September 2021 as other vaccine manufactures also start supply. India is a part of COVAX – a global initiative working towards global equitable access to COVID-19 vaccines. We will be sharing 50 % of our manufactured vaccine between India and COVAX at the same time. Initially, India will get more doses of the vaccine since global clearances will take an additional month or more to come through. Also India has such a large population so we will probably end up giving the majority of those 50 million doses to India first,’’ he said.

Vaccine for pneumonia

Giving details of SII’s pneumococcal conjugate vaccine, the company said it had been tailor-made for cases of pneumonia reported in India.

Mr. Poonawala said this would be the most affordable vaccine for pneumonia in the whole world. India’s drug regulator had granted market approval for the Pneumococcal Polysaccharide Conjugate vaccine, after reviewing the phase 1, 2 and 3 clinical trial data submitted by SII.

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.